HUM - Humana Inc.

NYSE - NYSE Delayed Price. Currency in USD
247.82
+5.60 (+2.31%)
At close: 4:01PM EDT
Stock chart is not supported by your current browser
Previous Close242.22
Open241.77
Bid0.00 x 1200
Ask0.00 x 800
Day's Range240.51 - 249.50
52 Week Range225.65 - 355.88
Volume1,389,096
Avg. Volume1,471,425
Market Cap33.464B
Beta (3Y Monthly)1.02
PE Ratio (TTM)19.40
EPS (TTM)12.77
Earnings DateJul 30, 2019 - Aug 5, 2019
Forward Dividend & Yield2.20 (0.86%)
Ex-Dividend Date2019-06-27
1y Target Est321.00
Trade prices are not sourced from all markets
  • These Louisville companies ranked on the 2019 Fortune 500 list
    American City Business Journals2 days ago

    These Louisville companies ranked on the 2019 Fortune 500 list

    Only two Louisville-based companies remain on the Fortune 500 list of the largest companies in the U.S.

  • Top Research Daily Reports for Walmart, American Tower & U.S. Bancorp
    Zacks2 days ago

    Top Research Daily Reports for Walmart, American Tower & U.S. Bancorp

    Top Research Daily Reports for Walmart, American Tower & U.S. Bancorp

  • Business Wire4 days ago

    Humana Spotlights Commitment to Addressing Social Determinants of Health in 2018 Corporate Social Responsibility Report

    Humana Inc. (HUM), one of the nation’s leading health and well-being companies, today released its 2018 Corporate Social Responsibility (CSR) report. In the comprehensive report, Humana details its continuing commitment to helping the individuals and communities it serves live their best lives by expanding and improving access to affordable healthcare. “At Humana, we see firsthand the impact that access to quality, affordable care has on our members and employees,” said Bruce D. Broussard, Humana’s President and Chief Executive Officer.

  • Former Humana employee pleads guilty to federal fraud charges
    American City Business Journals10 days ago

    Former Humana employee pleads guilty to federal fraud charges

    The former employee copied thousands of Amazon access codes that were used as rewards in Humana's Go365 fitness program.

  • CVS Stock Might Look Cheap, but It Is a Value Trap
    InvestorPlace11 days ago

    CVS Stock Might Look Cheap, but It Is a Value Trap

    If you follow social media, you'll see a ton of people calling CVS Health (NYSE:CVS) a compelling bargain right now. The stock sells for just over book value, 7.6x forward earnings, and offers a more than 3.5% dividend yield. For investors in the Peter Lynch "buy what you know" school of investing, CVS stock seems appealing. A respected company with omnipresent stores across the country selling at a deeply discounted valuation. So what's not to like?Source: Mike Mozart via FlickrThere are a few reasons for caution on CVS stock, despite the apparent positives. For one, the company has become far more than a pharmacy chain. And in its numerous acquisitions, it has loaded the company up with debt and risk.For another, the company's profit margins are under fire on many sides. The stock market isn't being unreasonable in pricing CVS stock for a series of difficult years ahead.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Great Stocks to Buy on Dips Dangerous Empire-BuildingI was never a fan of CVS' move into the pharmacy benefit manager (PBM) space. It may feel quite closely related to the main business; a PBM manages prescription benefits for self-insured companies, government organizations and other such entities that don't use a major health insurance operator. CVS could certainly achieve cost savings by fusing these two operations together, right?In practice, though, they are quite separate businesses. Dealing with private companies and Medicare is much different than running its pharmacies and walk-in clinics. As it would so happen, both retail pharmacy and PBMs have been struggling over the past few years, so CVS' diversification did little to alter its trajectory as compared with Walgreens Boots Alliance (NYSE:WBA).That said, CVS recently went all-in on becoming a one-stop health care destination. It made a gigantic $68 billion deal for health insurer Aetna. This was reportedly a defensive move, as Aetna itself was a major client of CVS' PBM. Buying them kept that business in-house rather than risking defection; it also took one major M&A target off the market. This was viewed as an important move to try to keep Amazon (NASDAQ:AMZN) from potentially entering the industry.Now, with the Aetna deal closed, CVS controls a significant chunk of the whole health care supply chain, from a walk-in flu shot on up through drug dispensing, Medicare management, and private health insurance. Deals Don't Inspire ConfidenceUnfortunately, this health care colossus faces a number of challenges. For one, management is showing questionable judgment. Its $12.7 billion acquisition of Omnicare in 2015 has already led to more than $6 billion in write-offs. CVS both misread that market in long-term care and also overestimated how many synergies there would be in the deal.This is problematic, since a large number of analysts believe CVS overpaid for Aetna. They offered a sizable premium to a stock that was already trading at all-time highs and was up exponentially heading into the deal. Aetna stock traded in the $20s a decade ago; CVS paid more than $200 per share.Interestingly, between 1977 and 2000, Aetna stock created only modest value for its shareholders. In a normal health care market, a health insurance firm should not spike in value nearly 10-fold inside of a decade. If you want to see why health care costs are soaring, the PBMs and the health insurers are a great place to look. Political Risk LoomsRecently, we've see a huge blame the other person game going on with health care costs. The drug companies say prescription pills are expensive because the PBMs and health insurers are overcharging everyone, taking way too much of a cut as middlemen. The health insurers are blaming the PBMs for overcharging them. The PBMs, in turn, have been blaming the pharmacies.This has been a profitable game for the past decade, everyone inflating costs while blaming someone else, but it won't and can't go on much longer. The health care system is simply too expensive for this sort of activity to drag on indefinitely.CVS is again promising huge synergies with the Aetna deal, but they won't get them. CVS is essentially competing against itself here in a way, as you have the entities that were all sticking each other with excessive costs now under one roof. With only CVS standing between the pharmaceutical company and the end patient, it will be far harder for CVS to wring so-called excessive profits out of this system.You see analysts expecting profit margins (which are already trending well downward) to continue dropping for both retail pharmacy and PBMs. Perhaps CVS felt compelled to buy Aetna as the health insurers are still doing better for the time being. These sorts of gains can't keep up if Medicare is going to remain solvent. Unfortunately for CVS, they top-ticked the market buying Aetna for an absurd price.Already shares of other health insurers have plummeted this year, with UnitedHealth (NYSE:UNH) and Humana (NYSE:HUM) both dropping around 30% since December.This fall has coincided with the rise of anti-private health insurance candidates such as Bernie Sanders for the 2020 presidential election. Health insurance costs will be a major campaign issue, and CVS has launched itself into the crossfire by paying up for Aetna. CVS Stock VerdictAs I mentioned, it's easy to make a case that CVS stock is cheap on valuation. However, there are several things to take into account before hitting the buy button. For one, CVS has a huge debt load post-Aetna, with its $70 billion debt just about equal to the company's market cap. The company's earnings will need to be channeled in large part to managing its debt rather than dividend hikes or share buybacks for the time being.Additionally, nearly all segments of the business are struggling. Retail pharmacy has issues, as results from Walgreens and Rite Aid (NYSE:RAD) have confirmed. PBMs have been weak in recent years, and now Aetna is at risk as the politicians threaten to regulate profits from that sector sharply lower or outlaw big chunks of the business entirely.Finally, CVS' management has not shown good discipline in dealmaking, first with the disastrous Omnicare deal and now this most questionable Aetna one. With the health care industry passing through such trying times, CVS stock is an easy avoid for the time being.At the time of this writing, Ian Bezek owned WBA stock. You can reach him on Twitter at @irbezek. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Great Stocks to Buy on Dips * 6 Growth Stocks to Buy for the Rest of 2019 * 4 Mega-Cap Stocks to Sell Before They Melt Down Compare Brokers The post CVS Stock Might Look Cheap, but It Is a Value Trap appeared first on InvestorPlace.

  • Humana Again Listed Among Top 50 Companies for Diversity
    Business Wire12 days ago

    Humana Again Listed Among Top 50 Companies for Diversity

    Humana Inc. (HUM) has again been named to The DiversityInc list of Top 50 Companies for Diversity, the most rigorous, data-driven analysis of diversity management practices in corporate America. Humana is No. 42 on the list, up from No. 48 last year. This extensive annual survey recognizes companies that excel in such areas as hiring, retaining and promoting women, minorities, people with disabilities, LGBTQ and veterans.

  • Business Wire12 days ago

    Partners in Primary Care to Open Five New Senior-Focused Primary Care Centers in Houston

    People with Medicare and Medicare Advantage in and around Houston will have access to senior-focused, primary care centers when Partners in Primary Care opens five new medical centers in the metro area. Partners in Primary Care, a subsidiary of Humana Inc. (HUM), is part of a family of senior-focused, primary care centers that deliver care to 35,000 Medicare Advantage patients.

  • Humana deal rumors brew (again) as hedge funds consider fighting mega deal
    American City Business Journals12 days ago

    Humana deal rumors brew (again) as hedge funds consider fighting mega deal

    Rumors are again rumbling around Louisville-based health care and insurance company Humana Inc. as two hedge funds mull opposing a health insurance mega-merger. Newswire service Reuters reported Monday that two hedge funds — Corvex Management LP and Sachem Head Capital Management LP — may oppose St. Louis-based Centene Corp.'s proposed $17.3 billion acquisition of Tampa, Fla.-based WellCare Health Plans Inc. Both companies are giants in the commercial and government-backed health plan industry. The report states that the hedge funds have stakes in Centene and believe that the company may be able to do more to find out if another company, such as Humana (NYSE: HUM), would be interested in acquiring Centene.

  • Insider Monkey13 days ago

    Activist Summary: Hedge Funds Are Targeting These Two Companies

    The world of activism is always…well, active. Logically. Looking at the current most interesting moves by activist hedge funds, Lion Point Capital, Corvex Management LP, and Sachem Head Capital Management LP come into the picture. Starting with Lion Point Capital that was launched four years ago by Didric Cederholm, who previously worked as an executive […]

  • Markit13 days ago

    See what the IHS Markit Score report has to say about Humana Inc.

    Humana Inc NYSE:HUMView full report here! Summary * Perception of the company's creditworthiness is negative * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is extremely low for HUM with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting HUM. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $1.58 billion over the last one-month into ETFs that hold HUM are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swap | NegativeThe current level displays a negative indicator. HUM credit default swap spreads are near their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Exclusive: Hedge funds target Centene, may oppose WellCare deal-sources
    Reuters13 days ago

    Exclusive: Hedge funds target Centene, may oppose WellCare deal-sources

    The hedge funds believe that Centene may be able to do more to find out if another company such as Humana Inc would be interested in acquiring it, the sources said. The hedge funds are seeking to take advantage of the fact that Centene needs to secure approval from its shareholders for the WellCare deal, according to the sources, who asked not to be identified because the matter is confidential.

  • Business Wire13 days ago

    Humana Inc. to Present at the Bank of America Merrill Lynch 2019 Health Care Conference

    Humana Inc. (HUM) announced today that Brian A. Kane, Chief Financial Officer, will make a presentation to investors at the Bank of America Merrill Lynch Health Care Conference on Tuesday, May 14, 2019, at 8:40 a.m. Pacific time. A live audio webcast of the presentation will be available via Humana’s Investor Relations page at humana.com.

  • Exclusive: Hedge funds target Centene, may oppose WellCare deal - sources
    Reuters13 days ago

    Exclusive: Hedge funds target Centene, may oppose WellCare deal - sources

    The hedge funds believe that Centene may be able to do more to find out if another company such as Humana Inc would be interested in acquiring it, the sources said. The hedge funds are seeking to take advantage of the fact that Centene needs to secure approval from its shareholders for the WellCare deal, according to the sources, who asked not to be identified because the matter is confidential.

  • ATL Healthiest Employers: Humana Inc. employees embrace wellness efforts
    American City Business Journals15 days ago

    ATL Healthiest Employers: Humana Inc. employees embrace wellness efforts

    Humana conducted a three-year study using participants in its Humana Go365, an online program that offers users personalized activities and then tracks and rewards them for reaching specific wellness goals.

  • Health Insurer Humana Holds 'Reversion to the Mean'
    Investopedia17 days ago

    Health Insurer Humana Holds 'Reversion to the Mean'

    Humana extended its earnings winning streak to 13 quarters in its May 1 report, but the cloud of health care uncertainty remains.

  • Thomson Reuters StreetEvents17 days ago

    Edited Transcript of HUM earnings conference call or presentation 1-May-19 1:00pm GMT

    Q1 2019 Humana Inc Earnings Call

  • Investing.com18 days ago

    Stocks: Tesla Soars, Shell, Cigna Rise in Premarket; Eventbrite Slumps

    Investing.com -- Stocks in focus in premarket trade on Thursday, May 2.

  • Stocks close lower after Fed chief Powell plays down chances of easier monetary policy
    MarketWatch18 days ago

    Stocks close lower after Fed chief Powell plays down chances of easier monetary policy

    Stocks close lower Wednesday, following a press conference by Fed Chair Jerome Powell, during which he played down the significance of falling inflation rates

  • Humana CEO decries 'Medicare for All' on earnings call: 3 takeaways
    American City Business Journals18 days ago

    Humana CEO decries 'Medicare for All' on earnings call: 3 takeaways

    Humana Inc. CEO Bruce Broussard took a dig at the idea of "Medicare for All" during the company's earnings conference call on Wednesday. "Humana does not support any bill that would eliminate Medicare Advantage or make private insurance illegal," Broussard, reading prepared remarks the company's (NYSE: HUM) call for the first quarter of 2019. A flash point in the conversation about the Medicare for All movement is the elimination of private health insurance.

  • Humana Inc (HUM) Q1 2019 Earnings Call Transcript
    Motley Fool18 days ago

    Humana Inc (HUM) Q1 2019 Earnings Call Transcript

    HUM earnings call for the period ending March 31, 2019.

  • Humana (HUM) Beats Q1 Earnings and Revenue Estimates
    Zacks18 days ago

    Humana (HUM) Beats Q1 Earnings and Revenue Estimates

    Humana (HUM) delivered earnings and revenue surprises of 4.19% and 1.99%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Reuters19 days ago

    Humana warns 2020 earnings will be hit by industry fee, rebate policy

    Humana Inc said on Wednesday it would not meet its earnings growth target for 2020 due to a $1.2 billion hit from an industry-wide fee and a proposal to overhaul rebates in health plans, sending its shares down as much as 5 percent. Investors have been cautious about potential changes to healthcare policy, including Senator Bernie Sanders' plan to shift all Americans to public health insurance and the Trump administration's proposed rule that would require insurers to pass on drug discounts to individual Medicare patients. It was put in place to help fund the implementation of former President Barack Obama's Affordable Care Act, but was suspended for 2017 and 2019.

  • Humana (HUM) Q1 Earnings & Revenues Beat Estimates, SurgeY/Y
    Zacks19 days ago

    Humana (HUM) Q1 Earnings & Revenues Beat Estimates, SurgeY/Y

    Humana's (HUM) first-quarter earnings benefit from Medicare Advantage membership growth and robust revenues.

  • Is Medicare for all doomed?
    Yahoo Finance Video16 days ago

    Is Medicare for all doomed?

    Many Americans struggle with high health care costs, and they want help from Washington. But that doesn’t mean they’re willing to give up private insurance. A recent Kaiser Family Foundation survey of people with employer-provided insurance finds that 68% say their plan is excellent or good. One-quarter say their coverage is average, with only 6% rating their plan as poor or failing. Overall, 72% say they’re “grateful” for their coverage.

  • Doctor on Demand CEO on partnership with Humana
    Yahoo Finance Video17 days ago

    Doctor on Demand CEO on partnership with Humana

    Doctor on Demand is the leading virtual care provider and has recently teamed up with Humana to launch "On Hand'-- a virtual primary care plan for Humana members. Hill Ferguson, CEO of Doctor on Demand, joined The Final Round to discuss the deal and how Doctors on Demand is changing the healthcare industry